PATIENTS AND METHODS

Twenty-one
LGSSs originating between 1983 and 1998 were retrieved from the archives of the Departments of Obstetrics and Gynecology and Pathology of the University of Graz, Austria. Haematoxylin and eosin (H&E)-stained sections were re-evaluated by two pathologists (SR and OR) and staged according to the guidelines of the 1994 WHO classification of tumours of the female genital tract (Scully et al, 1994) . All tumours were composed of cells resembling normal endometrial stromal cells and invaded the myometrium and usually its vascular spaces. Mitoses were fewer than 10/10 high-power fields (HPF = objective × 40) and necrosis was absent. The International Federation of Gynecology and Obstetrics (FIGO) stage for endometrial carcinoma was adapted for LGSS (stage I, tumours limited to the uterus; stage II, involvement of the cervix; stage III, involvement of the pelvis; and stage IV, disease outside the pelvis).
For quantitative immunohistochemical analysis one or two paraffin blocks with representative portions of the tumours were selected and 4-µm thick sections were stained with antibodies to ER (monoclonal, NCL-ER-6F11, Novocastra, UK) and PR (monoclonal, NCL-PGR-1A6, Novocastra, UK). The peroxidaseantiperoxidase method was used to detect the antigens. ER and PR expression was scored by two pathologists (SR and OR) with a scoring system based on both the percentage of positive tumour cell nuclei and the staining intensity (Remmele and Schicketanz, 1993) . The percentage of positive tumour cell nuclei was estimated on a four-tiered scale (< 10% = 1, 11-50% = 2, 51-80% = 3, >81% = 4). A four-tiered scale was also used to score the staining intensity (negative = 0, weak = 1, moderate = 2, strong = 3). The staining intensity was based on the predominant staining intensity in the tumour. The final immunoreactive score was obtained by multiplying the two scores. A final score of 0 was classified as negative, 1-3 as low, 4-6 as moderate and 8-12 as high. Receptorpositive breast carcinoma samples served as positive controls and normal human serum as negative controls. The mean age of the patients at surgery was 46 years (range 34-79) and only three patients were post-menopausal. Sixteen patients had surgical stage I, four stage III and one stage IV disease. The most common preoperative diagnosis was uterine leiomyomas. Twenty patients underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy. One patient had only exploratory laparotomy. Four patients (nos 2, 9, 14, 16) with stage III disease additionally had an omentectomy and one patient (no. 16) underwent pelvic lymphadenectomy. Four patients (nos 2, 9, 12, 16) received adjuvant chemotherapy, one patient (no. 14) received adjuvant radiation and 16 patients had no further treatment. Four patients were lost to follow-up and the median followup of the remaining 17 patients was 6.3 (1-14) years. All patients were followed through the Department of Obstetrics and Gynecology. Three patients (nos 7, 9, 16) developed pelvic recurrences and one patient (no. 10) had distant metastases in the lung and bone. One patient (no. 7) with pelvic recurrences at 2 and 8 years after initial presentation was reoperated and material for ER/PR determination was available. Two patients (nos 10, 14) died of disease and one patient (no. 4) of unrelated causes. None of the patients had hormonally active tumours or conditions such as polycystic ovarian disease or hyperthecosis that might be responsible for prolonged oestrogen stimulation of the endometrium (Press and Scully, 1985) .
RESULTS
Results are summarized in Table 1 . ER and PR were strongly expressed in the proliferative phase and early secretory phase of nontumour endometrial stroma of all premenopausal patients (Figure 1 ). ER were seen in 15 (71%) and PR in 20 (95%) LGSSs respectively (Figures 2-4) . ER expression was scored as high in three (14%), moderate in four (19%), and low in eight (38%) tumours. Six (29%)
LGSSs did not stain for ER, all of these tumours were positive for PR. PR expression was scored as high in eight (38%), moderate in ten (47%) and weak in two (10%) tumours. Only one (5%) LGSS did not stain for PR (this tumour was positive for ER).
LGSSs with a high score for ER or PR were uniformly positive throughout the tumour (Figure 2 ).
LGSSs with a moderate score demonstrated variable staining (Figure 3 ). In LGSSs with a low score the majority of tumour cells were negative. The staining intensity of the positive cells ranged from weakly to strongly positive ( Figure 4 ). The patient (no. 7) with pelvic recurrences 2 and 8 years after initial surgery showed successive loss of ER expression. ER expression was moderate in the primary tumour, low in the first recurrence, and absent in the second. PR expression was high in the primary tumour and both recurrences.
DISCUSSION
This is the first quantitative immunohistochemical study of ER/PR expression in LGSS. Most tumours expressed ER and PR, but expression of both receptors varied widely ranging from negative to strongly positive. CT: chemotherapy, RT: radiotherapy, NED: no evidence of disease, AWD: alive with recurrent disease, DWD: dead without disease, DOD: dead of disease, Lost: lost to follow-up, Cells: percentage of positive tumour cell nuclei (< 10% = 1; 11-50% = 2; 51-80% = 3; > 81% = 4) SI: staining intensity (negative = 0; weak = 1; moderate = 2; strong = 3), Score: Cells × SI, Interpretation: Score 1-3 as low; 4-6 as medium and 8-12 as high. Oestrogen and progesterone are important regulators of endometrial stromal function and act by binding to their nuclear receptors (Pickartz et al, 1990; Salmi et al, 1998) . Most previous studies of sex-steroid receptors in LGSSs were performed biochemically and were based on fewer than five cases of LGSSs (Baker et al, 1984; Lantta et al, 1984; Tsukamoto et al, 1985; Sutton et al, 1986; Katz et al, 1987; Navarro et al, 1992) . The reported concentrations of ER in tumour tissue ranged from 0 (Katz et al, 1987) to 1628 (Sutton et al, 1986 ) and of PR from 0 (Dunton et al, 1990) to 1811 (Dunton et al, 1990 ) fmol mg -1 cytosol protein. However, cytosol-based biochemical methods are not highly specific (Helin et al, 1990) . In breast carcinoma, immunohistochemical methods appear more sensitive, as they allow a better prediction of responsivness of the hormone therapy (Robertson et al, 1992) . In analogy to breast carcinoma, we were able to demonstrate heterogeneous expression of ER and PR in
LGSSs on a cellular level, which suggests different levels of susceptibility to hormonal therapy. Interestingly, in a patient with recurrent disease expression declined successively with each recurrence while PR expression remained high in both recurrences.
Several clinical observations suggest that LGSSs are sensitive to sex-steroid hormones. Katz et al (1987) reported four complete or partial responses with hormonal therapy. All four patients were alive and free of disease or alive with stable disease 2-6 years after initial diagnosis. Regression in size of metastases has been reported after bilateral oophorectomy (Baggish and Woodruff, 1972) and radiation-induced castration (Gloor et al, 1982) . A lower incidence of recurrence and longer disease free intervals after bilateral oophorectomy have also been reported (Krieger and Gusberg, 1973) . Recurrent disease has been successfully treated with progestins (Pellillo, 1968; Baggish and Woodruff, 1972;  Figure 1 ER expression in premenopausal nontumour endometrium, proliferative phase. ER are present in the stroma and epithelium of the glands. ER, peroxidase-antiperoxidase, original magnification × 100 Figure 3 LGSS with overall medium ER expression. Varying degrees of nuclear staining in the entire specimen indicate heterogeneous receptor expression (patient no. 6, score 4). PR, peroxidase-antiperoxidase, original magnification × 250 Figure 2 LGSS with overall low PR expression. Only individual cells or small groups of cells show strong nuclear staining while the majority of cells do not stain (patient no. 17, score 2). PR, peroxidase-antiperoxidase, original magnification × 250 Figure 4 LGSS with overall high PR expression with homogeneous strong nuclear staining in the absence of cytoplasmatic staining (patient no. 7, score 12). PR, peroxidase-antiperoxidase, original magnification × 200 Krumholz et al, 1973; Gloor et al, 1982; Baker et al, 1984; Tsukamoto et al, 1985; Keen and Philip, 1989; Montag and Manart, 1989; Rad and Lowe, 1990; Horowitz et al, 1996) . Scribiner and Walker (1998) reported preoperative treatment of LGSS with progestins. Anecdotal experience by Horowitz et al (1996) suggests that estrogen replacement therapy following a total hysterectomy and bilateral salpingo-oophorectomy in patients with LGSSs may increase the risk for recurrence. While the majority of LGSSs have been shown to contain ER and PR, not all responded to hormonal therapy. Sutton et al (1986) suggested that a critical threshold concentration of sex-steroid receptor is necessary for hormonal manipulation to be successful. The number of patients in our series is too small to analyse for associations between receptor status, hormone treatment and recurrence.
The heterogeneous expression of ER and PR receptors in our study may reflect receptor mutations with antigen loss and heterogeneous tumour populations (Richer et al, 1998) . The number of patients in our study is too low to speculate about any association regarding clinical behaviour and receptor status. The three patients with recurrence in our series varied widely in receptor expression. Conceivably, patients with LGSS could benefit from hormonal therapy based on the individual receptor status for primary and recurrent disease. In analogy to breast carcinoma, anti-oestrogens (Luo et al, 1997) , selective anti-oestrogen receptor modulators (Cummings et al, 1999) , progesterone (Bernoux et al, 1998) , antiprogesterone (Eldar-Geva and Healy, 1998), aromatase inhibitors (Miller et al, 1998) and luteinizing hormone-relasing hormone analogues (GNRH-A) (Vignali and Genazzani, 1998) might be useful in this setting. Hormone treatment might benefit patients with advanced disease for preoperative down-staging (Scribiner et al, 1998) or palliation, patients with disease confirmed to the uterus after hysterectomy, or patients with recurrence (Krumholz et al, 1973; Gloor et al, 1982) .
In conclusion, we suggest that, as in breast carcinoma, ER and PR should be routinely quantified in LGSSs by immunohistochemical methods.
